Trial abstract · §3
THYMALIN-RU-1 — results
Primary endpoint, absolute and relative effect where derivable, and harms as reported.
§3Results
§3.1Primary endpoint
Table 3. Primary endpoint as reported.
| Endpoint | Result as reported | Certainty |
|---|---|---|
| Immunological indices in older adults | The Institute has not obtained a retrievable protocol or analysis plan and grades claims for this compound very low certainty | Not rated |
| Reproduced from the published report. Where the report states a confidence interval the Institute reproduces it; where it does not, none is constructed. | ||
§3.2Endpoint hierarchy
§3.3Harms as reported
Table 5. Adverse events for Thymalin from the safety tables the Institute holds for this compound. Where a row names a different trial as its source, the figure is from that trial and not from this one.
| Event | Active, % | Comparator, % | Source trial |
|---|---|---|---|
| Injection-site reaction | — | — | Reported |
| Allergic reaction | — | — | A bovine-derived extract carries an inherent immunogenicity and allergy risk that a synthetic peptide does not |
| Transmissible agent risk | — | — | Any bovine-tissue-derived product carries a theoretical transmissible spongiform encephalopathy risk requiring documented sourcing controls |
Compound Evidence Institute · CEI-TR-0123/3 · https://compoundevidence.com/trials/thymalin-ru-1/results/ · retrieved 30 July 2026